Business Wire

FL-AMGTA

17.11.2020 14:01:06 CET | Business Wire | Press release

Share
AMGTA Publishes First Research Paper on Sustainability in Additive Manufacturing

The Additive Manufacturer Green Trade Association (AMGTA), a global trade group created to foster and promote the environmental benefits of additive manufacturing (AM), announced today the publication of its first commissioned university research project, a literature-based systematic review of the environmental benefits of metal AM. The paper, titled, “State of Knowledge on the Environmental Impacts of Metal Additive Manufacturing” was written by Dr. Jeremy Faludi from Delft University of Technology and Corrie Van Sice from Dartmouth College.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201117005440/en/

Key takeaways from the report include that, while “AM generally has much higher carbon footprints per kg of material processed than CM [conventional manufacturing] when considering the direct manufacturing process itself”, but “impacts depend greatly on part geometry—a solid cube will be much lower impact to produce by machining, while a hollow shell or lattice can be lower impact to produce by AM.” The report further recognizes the need for additional life cycle assessment (LCA) studies to quantify environmental impacts: “More LCA studies are necessary to definitively compare metal AM to CM; especially direct comparisons of AM to machining, and especially for technologies such as binder jetting and DED. These LCAs should ideally also include more of the product life cycle.”

“We were pleased to work with Dr. Faludi and Ms. Van Sice on this study,” said Sherry Handel, the Executive Director of the AMGTA. “No one should expect metal AM to be a more sustainable way to manufacture basic metal parts given the focused energy inherent in laser melting, but AM should present a more sustainable course for manufacturing finished precision components.” Ms. Handel continued, “These findings validate the AMGTA’s plans to provide the industry with rigorous, independent, and ongoing research. The AMGTA will continue to commission studies and publish research findings in an effort to update the industry and other key stakeholders on what our eco-footprint is now and what we will need to focus on in the future to be more sustainable.”

About the Researchers

Jeremy Faludi, Ph.D., a leading sustainable engineering researcher, was selected by the AMGTA to oversee this project. Dr. Faludi is assistant professor of design engineering at Delft University of Technology, where he specializes in sustainable design methods and green 3D printing, and adjunct faculty of engineering at the Thayer School of Engineering at Dartmouth College. Dr. Faludi earned a Ph.D. in Mechanical Engineering at University of California Berkeley, a Master of Engineering in Product Design at Stanford University, and a B.A. in Physics from Reed College.

Corrie Van Sice was a senior research engineer at the Faludi Lab at the Thayer School of Engineering, Dartmouth College. Ms. Van Sice managed the Green 3D Printing Lab and assessed AM techniques to define best practices for sustainability in the industry. Before joining the Faludi Lab, she was the lead Materials and Processes R&D Engineer at MakerBot Industries in Brooklyn, NY where she developed and scaled print material manufacturing. Ms. Van Sice earned a Master of Professional Studies from the Interactive Telecommunications Program at New York University in 2011.

About AMGTA

The AMGTA was launched in November 2019 to promote the environmental benefits of additive manufacturing (AM) over traditional methods of manufacturing. The AMGTA is a non-commercial, unaffiliated organization open to any additive manufacturer or industry stakeholder that meets certain criteria relating to sustainability of production or process.

Founding Members of the AMGTA include Sintavia, LLC , a leading additive manufacturer focused on the aerospace, defense, and space industry; Taiyo Nippon Sanso Corporation (one of the operating companies under Nippon Sanso Holdings Corporation), a supplier of stable industrial gases to a wide variety of global industries; and QC Laboratories, Inc. , an industrial and commercial non-destructive testing laboratory focused on AM components.

Participating Members of the AMGTA include AMEXCI AB , Danish AM Hub , EOS , GE Additive , Materialise , National Manufacturing Institute Scotland , Siemens Digital Industries Software , SLM Solutions Inc. , and Stryker .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye